Key Information Overview
Eli Lilly's weight loss drug has achieved remarkable clinical results in the treatment of metabolic diseases.
Retatrutide is a once-weekly injectable medication that targets three different gut hormones. On Thursday, the drug successfully completed a pivotal late-stage clinical trial. Obese participants receiving a maximum dose of 12mg lost an average of 28.3% of their body weight over the 80-week study period, equating to approximately 70.3 pounds, while those in the 9mg dose group averaged a weight loss of 64.4 pounds.
In contrast, the placebo control group achieved only a 2.2% weight loss.
About 45% of the 2,500 participants achieved a total weight loss of 30% or more, a feat traditionally only attainable through surgical weight loss procedures.
Lilly's Chief Scientific Officer and Product Officer Dan Skovronsky stated in an interview with CNBC that seeing a 30% weight reduction is “an incredible number.”
Comparison of Retatrutide with Existing Market Options
Retatrutide operates through a mechanism different from Lilly's existing products. The drug activates receptor sites for three hormones—GLP-1, GIP, and glucagon—while Zepbound employs a two-hormone approach, and earlier GLP-1 treatments utilized a single-hormone mechanism.
A novel 4mg dose evaluated in this study also caught analysts' attention. This lower dose achieved a 19% weight loss, comparable to high-dose Zepbound, but demonstrated better tolerability. Among participants receiving this dose, only 4% discontinued due to adverse events, compared to nearly 5% in the placebo group.
The safety profile of the drug is generally consistent with other GLP-1 medications. Gastrointestinal reactions such as nausea (42% at the maximum dose) and diarrhea (32%) were the most common side effects. No cardiovascular or liver issues were reported, alleviating some analysts' concerns regarding potential risks associated with the drug's glucagon activity.
Lilly reported an increased incidence of urinary tract infections compared to the placebo, but most cases were mild. Skovronsky noted that the occurrence of urinary tract infections may be related to the speed and extent of weight loss, pointing out that similar patterns have been observed after surgical weight loss.
Regulatory Outlook for Retatrutide
This marks the third successful late-stage study result for Retatrutide. The drug has already shown efficacy in diabetes studies earlier this year and achieved positive results in a smaller trial for obesity and knee osteoarthritis patients scheduled for December 2025.
TD Cowen analysts predict that the drug could generate $3.8 billion in annual revenue by 2030, assuming regulatory approval is granted.
According to company data, Lilly holds approximately 60% of the GLP-1 market share, while Novo Nordisk's Wegovy oral formulation has a presence in the market.